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Claude Dubray1,2,3 and Bruno Pereira5Abstract
Background: N-methyl-D-aspartate receptor antagonists are potential therapies for neuropathic pain, and
memantine has a good tolerance profile. A preclinical study recently reported that presurgery memantine may
prevent neuropathic pain development and cognition dysfunction. Considering the high prevalence of breast
cancer and of post-mastectomy neuropathic pain, a clinical trial is carried out to evaluate if memantine may prevent
neuropathic pain development and maintain cognitive function and quality of life in cancer patients.
Methods/Design: A randomized clinical trial (NCT01536314) includes 40 women with breast cancer undergoing
mastectomy at the Oncology Hospital, Clermont-Ferrand, France. Memantine (5 to 20 mg/day; n = 20) or placebo
(n = 20) is administered for 4 weeks starting 2 weeks before surgery. Intensity of pain, cognitive function, quality of
life and of sleep, anxiety and depression are evaluated with questionnaires. The primary endpoint is pain intensity
on a 0 to 10) numerical scale at 3 months post-mastectomy. Data analysis is performed using mixed models and
the tests are two-sided, with a type I error set at α = 0.05.
Discussion: The hypothesis of this translational approach is to confirm in patients the beneficial prophylactic effect
of memantine observed in animals. Such a protective action of memantine against neuropathic pain and cognitive
dysfunction would greatly improve the quality of life of cancer patients.
Trial registration: ClinicalTrials.gov: NCT01536314 on 16 February 2012
Keywords: Memantine, NMDA receptor, Breast cancer, Mastectomy, Chemotherapy, Neuropathic painBackground
Medical treatment of neuropathic pain (NP) is still far
from being satisfactory, with less than half the patients
achieving significant benefit with any pharmacological
drug [1]. Several therapies have been developed for the
treatment of NP but these methods are not equally ef-
fective for all NP patients. N-methyl-D-aspartate recep-
tor (NMDAR) antagonists such as ketamine, memantine
or dextromethorphan are potential drugs for NP allevi-
ation [2]. Evidence suggests that NMDAR within the dor-
sal horn plays an important role in both inflammation and* Correspondence: gisele.pickering@udamail.fr
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unless otherwise stated.nerve injury-induced central sensitization [3]. Activation
of NMDAR is associated with abnormalities in the sensory
(peripheral and central) system, resulting in neuronal exci-
tation and abnormal pain manifestations (spontaneous
pain, allodynia, hyperalgesia) [4]. Blocking these receptors
by antagonists leads to a reduction in pain [5]. A recent
review of the literature including 28 randomized clinical
trials [2] emphasizes the heterogeneity of doses used, the
diversity of pathologies generating neuropathic pain (post-
herpetic, post-amputation, diabetes and so forth) and
highlights the need to develop clinical trials of good meth-
odological quality with NMDA antagonists. NMDAR an-
tagonists, such as ketamine [6,7], are prescribed after
therapeutic failure with classical treatment but these drugs
have severe adverse events that limit their clinical use [8].
Another NMDAR antagonist, memantine, prescribed inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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minimal side-effects at doses within the therapeutic
range, probably because of its specific mechanism of ac-
tion as it is an uncompetitive antagonist with moderate
affinity, strong voltage-dependency and rapid unblocking
kinetics [9-11]. Concerning NP alleviation, memantine
shows controversial results in human studies [6,12-15].
We recently demonstrated for the first time in an
animal surgical NP model, that memantine prevents
the development of NP symptoms and the impairment
of spatial memory [16]. With a translational approach,
we present a clinical study where memantine (versus
placebo) is administered 2 weeks before and 2 weeks
after mastectomy in 40 women suffering from breast
cancer. Confirmation of preclinical results in this clin-
ical study would constitute a major step for NP preven-
tion by memantine and maintenance of cognition and
quality of life in these vulnerable patients.Methods/Design
We are conducting a randomized, placebo-controlled
clinical trial in the Oncology Hospital, Clermont-
Ferrand, France, in 40 women undergoing total mast-
ectomy for breast cancer. The study has been approved
in December 2011 by the regional Ethics committee
(CPP Sud-Est, France, number AU917) and registered
on 16 February 2012 at “http://www.clinicaltrials.gov”
(NCT01536314). Women provide written informed
consent prior to their participation in the study during
their anesthesiology visit. After baseline assessments (day
(D)−15) of pain intensity, cognition, quality of life and qual-
ity of sleep questionnaires, participants are randomized
into two parallel groups: memantine (n = 20) or placebo
(n = 20). Memantine or placebo (lactose) is given orally for
4 weeks starting 2 weeks before surgery. Memantine is
given in increasing doses: 5 mg/day for 3 days; 10 mg/
day for 3 days; 15 mg/day for 3 days and 20 mg/day for
5 days. Endpoints are reassessed 15 days (D0+15),
3 months (D0 + 3 months) and 6 months (D0 + 6 months)
post-mastectomy. In order to maintain a good compli-
ance and to verify that women do not develop adverse
events, patients are called once a week by phone. A
booklet for monitoring is completed daily by the patient
for 6 months from the day of surgery. Detailed informa-
tion on the present study is summarized in Figure 1.Eligibility
Inclusion criteria
Women are eligible for this study if they are at least
18 years old, with a diagnosis of breast cancer, pro-
grammed for mastectomy with or without axillary dis-
section, able to understand and willing to follow the
study protocol.Exclusion criteria
Exclusion criteria comprise contraindications for meman-
tine and hypertension, severe cardiac insufficiency or dia-
betes (Type I and II), alcohol addiction and treatment
with specific drugs (amantadine, ketamine, dextromethor-
phan, L-Dopa, dopaminergic, anticholinergic agonists,
barbituric, neuroleptic, IMAO, antispastic agents, dantro-
len or baclofen, phenytoin, cimetidine, ranitidine, procain-
amide, quinidine, quinine, nicotine, hydrochlorothiazide,
warfarin). Childbearing age, no use of effective contracep-
tive method, pregnancy or lactation, involvement in an-
other clinical trial and inability to comply with the
requirements of protocol are other exclusion criteria.
Objectives
The primary objective of this study is to evaluate if
memantine administered before and after mastectomy
may prevent pain development at 3 months post-
mastectomy when compared to the placebo group. The
endpoint at 3 months was chosen because chronic pain
is usually defined as pain lasting longer than 2 to
3 months [17,18], and 6 months was included as a sec-
ondary endpoint.
The secondary objectives are to estimate at 3 and
6 months post-mastectomy the pain intensity, the anal-
gesic concomitant medications, the impact of treatment
(memantine/placebo) on cognitive function, quality of
life, sleep, anxiety and depression, the impact of cancer
chemotherapy-induced pain and cognitive impairment
and the prevalence of phantom breast experience.
Definition of endpoints and outcome measures
Primary endpoint
The primary endpoint is the pain intensity evaluation by
numerical scale in memantine and placebo groups at
3 months post-mastectomy. The scale ranges from 0 (no
pain) to 10 (maximal tolerable pain).
Secondary endpoints
Secondary endpoints are the evaluation of pain at the
screening visit, at 2 weeks, 3 months and 6 months after
mastectomy (numerical scale, Brief pain Inventory, Mc-
Gill pain questionnaire), neuropathic pain (Neuropathic
Pain in 4 questions, Neuropathic Pain Symptom Inven-
tory), cognition (Trail Making Test, Digit Symbol Substi-
tution Test), sleep (Leeds sleep questionnaire), quality of
life (Short-Form-36), and anxiety and depression (Hos-
pital Anxiety and Depression scale). The summary of the
different evaluations for a patient is reported in Table 1.
Brief Pain Inventory This self-administered question-
naire provides information on the intensity of pain,
along with the degree to which the pain interferes with
the everyday functioning of life including: mood, walking,





Hospital stay Follow-up Follow-up Follow-up
Day of visit D0-15 D0 D0 to D0 + 15 D0 + 15 D0 + 3 months D0 + 6 months
Filling of questionnaires
1- Pain
Numerical Scale + - + + + +
DN4 + - - + + +
NPSI - - - + + +
BPI - - - - + +
McGill pain questionnaire - - - - + +
2- Cognition
Trail Making Test + - - + + +
Digit Symbol Substitution Test + - - + + +
3- Quality of life
SF-36 + - - + + +
4- Sleep
Leeds questionnaire + - - + + +
5- Anxiety/Depression
HAD scale + - - - + +
6- Concomitant medication recording
Treatments (analgesics, antidepressants, etc.) + + + + + +
+, Questionnaire performed; -, questionnaire not carried out; BPI, Brief Pain Inventory; DN4, Neuropathic Pain in 4 questions; HAD scale, Hospital Anxiety and
Depression Scale; NPSI, Neuropathic Pain Symptom Inventory; SF-36, Short-Form-36.
Figure 1 Study design.
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life [19].
McGill pain questionnaire This questionnaire allows
the patient to describe pain experienced during the last
48 hours [20]. It has fifty eight qualifiers divided into
sixteen items (A to P). Each qualifier is rated from 0 to
4, where 0 = absent, 1 = low, 2 = moderate, 3 = strong,
4 = very strong. The score is divided between two sub-
classes: sensory subclass (items A to I) and emotional
subclass (items J to P).
Neuropathic pain: “Neuropathic Pain in 4 questions”
Neuropathic pain in four questions is a clinical tool for
the diagnosis of neuropathic pain [21]. This question-
naire has four questions divided into 10 items related to
the interview (that is, symptoms) and to the sensory
examination (that is, signs). The investigator asks and
examines the patient and notes a response “no” or “yes”
for each item: “yes” is scored as “1” and “no” is scored as
“0”. The sum of scores gives the total score of the patient
(out of 10). Neuropathic pain in four questions is con-
sidered as positive if the patient obtains a score of 4/10.
Neuropathic Pain Symptom Inventory Neuropathic
Pain Symptom Inventory is a self-questionnaire and in-
cludes 10 pain descriptors [22]. Intensity is rated on 0 to
10 numerical scales and two temporal items are de-
signed to assess spontaneous ongoing pain duration and
the number of pain paroxysms over 24 hours. This ques-
tionnaire discriminates five distinct clinically relevant di-
mensions: spontaneous burning pain, spontaneous deep
pain, paroxysmal pain, evoked pain, and paresthesia/
dysesthesia.
Trail Making Test This non-verbal cognitive test as-
sesses the ability of speed, executive functions, attention,
concentration, and visual perceptual speed [23,24]. The
test takes place in two parts: in Part A, circles are num-
bered from 1 to 25 and the patient must connect with
lines the numbers in ascending order (1-2-3-4, and so
forth); in Part B, the circles contain numbers from 1 to
13 and letters from A to L, the patient must connect the
circles with lines but alternating numbers and letters
(1A-2B -3C, and so forth). The patient must connect the
circles as quickly as possible for both parts of the test,
without lifting the pen from the paper. The Trail Making
Test B additionally provides an estimate of mental
flexibility.
Digit symbol substitution test The digit symbol substi-
tution test is a neuropsychological, non-verbal test,
which assesses cognitive deficit and brain damage associ-
ated with aging and/or depression [25]. It also evaluateslearning ability, concentration and attention. It consists
of combining pairs of symbols and numbers as quickly
as possible and the score is the correct number of sym-
bols in the time allowed (for example, 90 or 120
seconds).
Short-Form 36 The Short-Form-36 is a questionnaire
evaluating the quality of life of patients [26,27]. It is a
multidimensional scale that assesses the health and qual-
ity of life. This scale can be performed in self- or hetero-
questionnaire with 36 items including nine dimensions:
physical function, role physical, bodily pain, general
health, vitality, social functioning, role emotional, mental
health and health thinking.
Leeds sleep questionnaire The Leeds sleep evaluation
[28,29] questionnaire is a standardized self-administered
questionnaire composed of ten visual analogue scales
that relate to four aspects of sleep efficiency: quality of
sleep, getting to sleep (visual scales 1, 2 and 3); sleep
quality (visual scales 4 and 5); awakening from sleep
(visual scales 6, 7 and 8); and behavior following wake-
fulness (visual scales 9 and 10).
Hospital Anxiety and Depression scale (HAD) The
Hospital Anxiety and Depression scale is a self-
administered questionnaire in 14 items completed by
the patient [30]. It is used to determine the levels of anx-
iety and depression. Seven of the items relate to anxiety
and seven relate to depression.
Randomization, allocation concealment and blinding
Women with breast cancer are informed by their
anesthetist 2 to 3 weeks before mastectomy. On the day
of the visit, inclusion and exclusion criteria are verified
and written informed consent is obtained by the
physician. After clinical examination and pain evalu-
ation, the patient fills in the questionnaires. A clinical
nurse independent from the protocol obtains the
randomization number from the hospital pharmacy
and the patient is then randomized in the memantine
or placebo group. Treatment allocation follows a pre-
determined randomization list and is generated using
random blocks. Memantine and placebo treatments
are packed in similar blisters covered with an identical
label indicating batch number, expiry date and sponsor
code with no indication of the name of the drug. The
nurse gives the treatment to the patient in an inde-
pendent room after questionnaires have been filled. In
order to maintain blinding, the consent physician (who
evaluates pain, the main endpoint of the study) cannot
guess allocation at any time and does not see the pa-
tient again before they leave hospital.
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The number of subjects required is 40 chronic pain pa-
tients (20 in each group). The minimum δ difference in
numerical scale pain between memantine and placebo
groups at 3 months is estimated at 1.6 and σ standard
deviation at 1.5, estimated from published data of the
literature [31,32], with α = 0.05 two-sided situation and
β = 0.10.
Statistical analysis
Statistical analyses will be performed with Stata software
(version 13, StataCorp, College Station, USA). Concern-
ing the primary objective, comparison between the ran-
domized groups will be performed using an analysis of
covariance with baseline score as a covariate [33]. The
correlation between baseline and follow-up scores was
also proposed. For other secondary parameters, the
comparisons between the randomized groups will be
performed using the Student test or the Mann–Whitney
test (if the conditions for validity of the Student test are
not met, normality will be verified by the Shapiro-Wilk
and homoscedasticity by the Fisher-Snedecor test). To
study the evolution of the main endpoint (numerical
scale pain), data analyses will be performed using mixed
models which allow us to consider, on the one hand,
time, group and interaction time versus group as fixed ef-
fects, and, on the other hand, the within- and between-
subject variability in order to visualise the assumption of a
difference at 2 months between the two randomized
groups that increases up to 3 months and stabilizes at 6
months. Residual normality will be checked for all consid-
ered models. When appropriate, anticancer chemotherapy
(yes/no) will be studied as a fixed effect in these models
before considering subgroup analyses. The comparison
between the treatment groups will be performed syste-
matically: (1) without adjustment; and (2) by adjusting
other factors whose repartition could be, despite the
randomization, unbalanced between the treatment groups.
The tests will be two-sided, with a type I error set at α =
0.05. A sensitivity analysis of missing data will be per-
formed to ensure the pertinence of the longitudinal data
(MAR (Missing at random) or MCAR (Missing com-
pletely at random)). In order to assess the problem caused
by missing longitudinal data at 6 months, estimation
methods developed by Verbeke and colleagues [34] will be
proposed.
Discussion
NP is difficult to treat and NMDAR antagonists, such as
ketamine, dextromethorphan or memantine [5,6,35], are
potential drugs for persistent pain. Memantine has
shown its efficacy in some studies [15,36] and presents
the advantage of having less adverse effects than keta-
mine [8-11]. We have shown in a surgical pain modelthat memantine prevents NP symptoms such as tactile
allodynia and mechanical hyperalgesia when adminis-
tered a few days before surgery [16]. These findings
needed to be confirmed in patients during the post-
operative period. Mastectomy is known to generate NP
in 23% patients at 3 months post-surgery [37], 42% at 5
years [38] and 37% at 9 years post-mastectomy [39].
Cancer patients undergoing surgery may also develop
NP associated with cancer chemotherapy. It is well
known that 25% to 50% of patients treated with chemo-
therapeutic agents such as taxane, vinca alkaloid and
platinum classes develop peripheral neuropathy syn-
drome. Patients with chemotherapy-induced NP display
a set of neuropathic pain symptoms that are characte-
rized by stinging, tingling, numbness, changes in sensiti-
vity, burning sensations or electric shocks [40]. The
incidence of chemotherapy-induced NP depends on the
type of chemotherapeutic agents, the dose administered
and the cumulative dose.
This trial of prophylactic memantine given long before
surgery in cancer patients aims to evaluate if memantine
may diminish overall post-surgery pain and prevent NP
development. It aims also to evaluate the concomitant
impact on cognition and quality of life. We showed in
animals that pre-surgery memantine prevents cognition
impairment [16]. Breast cancer as well as chronic pain
induced by chemotherapy may be associated with cogni-
tive dysfunction [41] and impairment of health-related
quality of life, quality of sleep, anxiety and/or depression
[42]. Indeed, cognitive impairment may be due to the
diagnosis of the pathology, to surgery [41] and also to
chemotherapy, as cognitive deficit is described in 20-
30% to 75% of women having chemotherapy-induced
NP [43,44].
Given that mastectomy with or without chemotherapy
can induce NP and cognitive and emotional impairment,
these complications represent a real burden for women
with breast cancer, and global care is a priority to
improve their well-being. If our study confirms preclin-
ical results, memantine given before mastectomy could
be a new prophylactic strategy to counteract NP deve-
lopment. It would provide a preventive therapeutic
innovation to decrease the incidence of post-operative
and chemotherapy-induced NP, cognitive impairment
and quality of life impairment and comorbidities that
generally accompany breast cancer pathology.
Trial status
Recruitment started in March 2012.
Abbreviations
NMDAR: N-methyl-D-aspartate receptor; NP: neuropathic pain.
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